U.S. should expedite AstraZeneca vaccine authorization before new Covid variants spread - Dr. Peter Hotez

New COVID variants identified in Florida: more cases found in California

“We’re all high fiving ourselves because the numbers are going down, and I am saying that we are in the eye of the hurricane, and the next big wave is coming,” said Hotez.
Average daily cases of coronavirus in the U.S. have dropped about 57%, according to a CNBC analysis of Johns Hopkins data.
Hotez urged that now is the time the U.S. should really be making a push to vaccinate, especially before even more Covid variants spread.

Dr. Peter Hotez told CNBC’s “The News with Shepard Smith” that individuals in the U.S. ought not become careless as a result of dropping Covid cases, particularly in the midst of new reports of another variation, B.1.526, spreading in New York.

“We’re all high fiving ourselves in light of the fact that the numbers are going down, and I am saying that we are in the eye of the storm, and the following large wave is coming,” said Hotez, co-head of the Center for Vaccine Development at Texas Children’s Hospital.

Normal day by day instances of Covid in the U.S. have dropped about 57%, as per a CNBC investigation of Johns Hopkins information. A few states, be that as it may, are not seeing as sharp of a decay. Vermont is just down 22% in normal day by day cases, New York down about 45%, Oregon almost 47%, and Florida is down 48% in every day normal cases. Hotez singled Florida out for the pervasiveness of a profoundly contagious Covid variation in the express that was first found in the U.K.

“The one express that truly interests me, not really positively, is Florida, since we are hearing that about 10% of the infection confines emerging from Florida is that B.117 variation that emerged from the United Kingdom,” said Hotez in a Wednesday night meet.

Hotez asked that this is the ideal opportunity the U.S. should make a push to immunize, particularly before more Covid variations spread. While AstraZeneca announced that it anticipates that its vaccine should be approved in the U.S. in April, Hotez said, “I think once in a while we need to consider calling the discernible” and ought to approve it sooner.